Anti-CD40L antibody frexalimab slows new brain lesions in multiple sclerosis

Nat Med. 2023 Aug;29(8):1882-1883. doi: 10.1038/d41591-023-00060-4.

Thiago Carvalho

PMID: 37407835 DOI: 10.1038/d41591-023-00060-4

Products

Cat. No.

Product Name

Description

Target

Research Area
HY-P99625

Frexalimab

Anti-CD40L mAb

TNF Receptor

Inflammation/Immunology

MedChemExpress Magic Cece

MedChemExpress: Contact Us; About Us; Headquarters; Distributors; Statement on False Report; Careers

Customer Support: Technical Support; Service; Ordering Information; Easy Return; Shipping Rates & Policies; Intellectual Property Promise

Resources: Free Sample; Resources; Molarity Calculator; Dilution Calculator; Terms & Conditions; Reconstitution Calculator; Specific Activity Calculator

Subscribe to our E-newsletter

Name
Email *

	Sorry, but the email address you supplied was invalid.

Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.

Copyright © 2013-2024 MedChemExpress. All Rights Reserved.: Site Map Privacy Policy

Join with us